Hana Pharm하나제약
293480 · KOSPI · ₩293480 · 하나제약
- Market cap
- ₩145B
- Enterprise value
- ₩199B
- P/E
- 12.4×
- P/B
- 0.4×
- Dividend yield
- 3.2%
- ROE
- 3.5%
- Net margin
- 4.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−31.9% from the high
₩8,050Today: ₩8,170 – ₩8,240₩11,990
Returns
- 1W−1.7%
- 1M+0.1%
- 3M−1.9%
- 6M−17.2%
- YTD−27.2%
- 1Y−31.6%
- Volume today
- 13,779
- 0.9× the 20-day average
- Traded today
- ₩113M
- Listed shares
- 17,772,946
- EPS (12 months)
- ₩658
- Earnings yield 8.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumFlat0.2% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Hana Pharm stock overview
Hana Pharm (하나제약, KRX: 293480) is listed on KOSPI, in the Biotech & Pharma sector. The company manufactures and sells prescription drugs, with a particular strength in narcotic painkillers and anesthetics, where it ranks among the leaders in those markets. Its shares closed at ₩8,170 on Oct 27, 2026, down 0.49% on the day, giving it a market value of ₩145B.
Key facts
- Market cap
- ₩145B
- Sector
- Biotech & Pharma
- Latest price change
- −0.49%
- As of
- Oct 27, 2026
- Main business
- The company manufactures and sells prescription drugs, with a particular strength in narcotic painkillers and anesthetics, where it ranks among the leaders in those markets.
Quick answers about Hana Pharm
- What does Hana Pharm do?
- The company manufactures and sells prescription drugs, with a particular strength in narcotic painkillers and anesthetics, where it ranks among the leaders in those markets. Its portfolio of roughly 380 National Health Insurance-listed products also spans cardiovascular, painkiller, digestive, neurology and dermatology medicines, supplied mainly as injectables and oral tablets. It sells primarily to general hospitals, hospitals and clinics across South Korea, and operates manufacturing plants in Hwaseong, Gyeonggi Province, with an R&D research center in Pangyo.
- What is the market cap of Hana Pharm?
- The market capitalisation of Hana Pharm was ₩145B at the close on Oct 27, 2026.
- Who are the largest shareholders of Hana Pharm?
- According to the latest official filings, the largest reported holders are Jo Dong-hoon (57.71%, as of Oct 28, 2024); Jo Ye-rim (11.75%, as of Jun 2, 2026); Jo Hye-rim (11.70%, as of Jun 2, 2026).
- When is the next earnings report from Hana Pharm?
- Korean companies rarely announce results dates in advance. Based on when Hana Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Hana Pharm?
- Yes. The National Pension Service held 0.63% of Hana Pharm shares as of Dec 31, 2025.
Company profile
The company manufactures and sells prescription drugs, with a particular strength in narcotic painkillers and anesthetics, where it ranks among the leaders in those markets. Its portfolio of roughly 380 National Health Insurance-listed products also spans cardiovascular, painkiller, digestive, neurology and dermatology medicines, supplied mainly as injectables and oral tablets. It sells primarily to general hospitals, hospitals and clinics across South Korea, and operates manufacturing plants in Hwaseong, Gyeonggi Province, with an R&D research center in Pangyo.
Written by AI from the company's latest annual report.
- Korean name
- 하나제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 최태홍
- Founded
- Jan 1978
- Listed
- Oct 2018
- Listed shares
- 17,772,946
- Fiscal year ends
- Month 12
- Website
- www.hanaph.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- [Corrected] New Facility Investment, etc.Oct 16, 2026
- Insider shareholding reportAug 27, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- [Amended] Designation as Insincere Disclosure CompanyJul 3, 2026
- Designation as Company for Unfaithful DisclosureJul 3, 2026
Titles in Korean until English translations are added.
Also known as: Hana Pharm / 하나제약 / 293480 / KRX:293480
Source: KRX statistical information